Effectiveness of sacubitril/valsartan for patients with cancer therapy‑related cardiac dysfunction: A systematic review of descriptive studies

  • Authors:
    • Yun Huang
    • Yuyu Zhang
    • Weifeng Xu
    • Chongbo Fang
    • Hua Zhou
    • Lili Ma
  • View Affiliations

  • Published online on: February 2, 2023     https://doi.org/10.3892/ol.2023.13694
  • Article Number: 108
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present review assessed the effectiveness of sacubitril/valsartan in patients with cancer therapy‑related cardiac dysfunction (CTRCD). Studies that included patients with CTRCD treated with sacubitril/valsartan were retrieved from the Medline, Embase, Cochrane Library and ClinicalTrials databases. Only descriptive studies on sacubitril/valsartan for patients with CTRCD were included in this review; therefore, all variables were qualitatively analyzed. A total of five studies comprising 109 patients were included. The duration from anticancer therapy to heart failure (HF) or from HF to the use of sacubitril/valsartan exhibited interindividual variations. In patients with CTRCD who were treated with sacubitril/valsartan, the left ventricular ejection fraction improved, N‑terminal pro‑B‑type natriuretic peptide levels decreased and exercise tolerance improved, as indicated by the change in the New York Heart Association functional class. These clinical, echocardiographic and biochemical improvements were found for different dosages or treatment durations of sacubitril/valsartan. No difference was found between the baseline and follow‑up serum creatinine and potassium levels. These findings, which are limited to descriptive studies, support the effectiveness of sacubitril/valsartan in improving heart function following CTRCD.
View Figures
View References

Related Articles

Journal Cover

March-2023
Volume 25 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Huang Y, Zhang Y, Xu W, Fang C, Zhou H and Ma L: Effectiveness of sacubitril/valsartan for patients with cancer therapy‑related cardiac dysfunction: A systematic review of descriptive studies. Oncol Lett 25: 108, 2023.
APA
Huang, Y., Zhang, Y., Xu, W., Fang, C., Zhou, H., & Ma, L. (2023). Effectiveness of sacubitril/valsartan for patients with cancer therapy‑related cardiac dysfunction: A systematic review of descriptive studies. Oncology Letters, 25, 108. https://doi.org/10.3892/ol.2023.13694
MLA
Huang, Y., Zhang, Y., Xu, W., Fang, C., Zhou, H., Ma, L."Effectiveness of sacubitril/valsartan for patients with cancer therapy‑related cardiac dysfunction: A systematic review of descriptive studies". Oncology Letters 25.3 (2023): 108.
Chicago
Huang, Y., Zhang, Y., Xu, W., Fang, C., Zhou, H., Ma, L."Effectiveness of sacubitril/valsartan for patients with cancer therapy‑related cardiac dysfunction: A systematic review of descriptive studies". Oncology Letters 25, no. 3 (2023): 108. https://doi.org/10.3892/ol.2023.13694